# Dysbiosis of intestinal microbiota in patients with neuromyelitis optica spectrum disorders

## TL;DR

This study found that patients with NMOSD have distinct gut microbiomes and metabolite profiles, which improve after immunosuppressive treatment.

## Contribution

The study identifies specific gut microbiota and metabolic changes in NMOSD patients and shows treatment effects on these profiles.

## Key findings

- NMOSD patients had higher gut microbial diversity and distinct microbial abundances compared to healthy controls.
- Immunosuppressive treatment for six months reduced microbiome and metabolite differences between NMOSD patients and controls.
- Altered gut microbiota and metabolites in NMOSD suggest potential therapeutic targets for future interventions.

## Abstract

This study aimed to explore the specific microbial signatures and metabolomic profiles of fecal microbiota in patients with neuromyelitis optica spectrum disorders (NMOSD) and assess the effects of immunosuppressants on their gut microbiota using a longitudinal cohort study.

We enrolled 21 treatment-naïve NMOSD patients and 21 matched healthy controls (HCs). Fecal microbial composition and metabolomic profiles were compared between groups using 16S rRNA gene sequencing and ultra-high-performance liquid chromatography-mass spectrometry. Subsequently, fecal samples from NMOSD patients were collected and reassessed after immunosuppressant treatment.

The gut microbial composition and metabolomic profiles of NMOSD patients were distinct from those of HCs. The α-diversity metrics were significantly higher in NMOSD patients than in HCs (P <0.001). Microbiome alterations in NMOSD patients were characterized by increased abundances of Streptococcus and Ruminococcus, and decreased abundances of Faecalibacterium, Ralstonia, and Pseudomonas at the genus level (all with linear discriminant analysis scores > 4 and P < 0.001). Additionally, Phylogenetic Investigation of Communities by Reconstruction of Unobserved States analysis identified 19 differentially abundant metabolites and 44 altered metabolic pathways in NMOSD patients compared to HCs. Immunosuppressive treatment for over six months may reduce these differences, shifting the gut microbiota composition and metabolite profiles of NMOSD patients closer to those of HCs.

Our study revealed significant gut microbiome dysbiosis and metabolic abnormalities in patients with NMOSD, which were markedly alleviated after six months of immunosuppressive treatment. These preliminary findings suggest the gut microbiota biomarkers could serve as potential therapeutic targets in the future.